Loading...
•
Jun 30
ORIC Pharmaceuticals Q2 2025 Earnings Report
ORIC Pharmaceuticals reported a net loss in Q2 2025 with no revenue, while maintaining strong cash reserves and progressing its clinical programs.
Key Takeaways
In Q2 2025, ORIC Pharmaceuticals posted a net loss of $21.4 million with no revenue as it continues to focus on advancing its clinical-stage oncology programs. The company reported a decrease in R&D expenses compared to the prior year and ended the quarter with $233.6 million in cash and investments.
Reported a net loss of $21.4 million for Q2 2025.
No revenue was generated during the quarter.
R&D expenses declined to $14.9 million from $18.5 million in Q2 2024.
Cash, cash equivalents, and investments totaled $233.6 million as of June 30, 2025.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC expects its cash and investments to fund operations into H2 2027 as it progresses multiple clinical programs and anticipates upcoming data readouts.
Positive Outlook
- Cash runway extended into the second half of 2027.
- ORIC-114 trial enrollment completed in patients with EGFR and HER2 exon 20 mutations.
- Dose expansion cohorts underway in ORIC-533 multiple myeloma trial.
- Initiation of Phase 1b trial for ORIC-944 expected in H2 2025.
- Encouraging preclinical data for ORIC-613 targeting PLK4.
Challenges Ahead
- Continued net losses with no revenue generation.
- R&D and G&A expenses continue to impact bottom line.
- Dependency on successful clinical trial outcomes.
- Potential delays or setbacks in regulatory timelines.
- High reliance on capital markets for future funding.